Matthew Wright

In a major commercial milestone, ReNerve has announced its flagship NervAlign nerve cuff has been approved for use across the US Department of Defense (DoD) and Veterans Affairs (VA) healthcare systems. #ASX $RNV buff.ly/M21De0J

We’ve received Rare Pediatric Disease Designation from the US FDA for NTI164 in Rett syndrome. This milestone recognition complements the existing Orphan Drug Designation and strengthens our position in developing therapies for rare and underserved neurological disorders. The…

We have entered into a non-binding agreement with Nyos Metals & Yoro Metals to acquire a 100% interest in several exploration applications located in the Republic of Cameroon and the Republic of Congo: buff.ly/WasMAch #RB6

We’re incredibly grateful to patient Brendan Roberts for bravely sharing his journey with lymphoma on 7NEWS Australia last night, as well as to journalist Amber Laidler and Associate Professor Matthew Ku from Royal Prince Alfred Hospital for highlighting the potential of our…

Our CEO, Gary Phillips, presented in the "Finding the Next 10x" session at the 2025 Bioshares Biotech Summit in Hobart, outlining Syntara’s pipeline of first-in-class therapies for fibrotic diseases, including myelofibrosis and skin scarring. Thank you to Bioshares for the…

We’ve wrapped up at the 2025 Bioshares #Biotech Summit, where CEO Dr Rebecca McQualter presented in the “Finding the Next 10x” session, sharing progress on $CHM CDH17 and our clinical pipeline.

Our Managing Director & CEO, Anthony Filippis joined today’s “Deal Making: The Real Story” panel at the 2025 Bioshares Biotech Summit, alongside fellow biotech leaders sharing real-world lessons on navigating transactions, partnerships, and growth. Thanks to Bioshares for…

“There’s a big gap in breakthrough cancer pain treatment… and IRX‑211 addresses that gap.” Dr Sud Agarwal shares why IRX‑211 is gaining strong clinician support as we prepare for Phase 2 dosing. Watch the full $IRX Town Hall: youtu.be/IC6KoFuOoHM?si…

We've commenced initiation of AZALOX, a Phase 1b/2 multi-centre study evaluating amsulostat (SNT-5505) in combination with 5-Azacitidine for the treatment of high-risk Myelodysplastic Neoplasms (MDS) and Chronic Myelomonocytic Leukemia (CMML). The study, supported by German…

📰 Media coverage by @Inside_PM Take II: Off-the-Shelf CAR T Shines in Relapsed/Refractory Lymphoma Patients Read the full article here: insideprecisionmedicine.com/topics/oncolog… #IMU #ASX #ASXNews

“This would be the first approved drug that’s modifying the whole way that a scar develops.” Thank you to @7NewsAustralia and reporter @amberlaidler7 for covering our work to change what’s possible in the treatment of scarring. Our next-generation topical anti-fibrotic drug is…

Euroz Hartleys has initiated research coverage for @SyntaraTx (ASX:SNT) with a A$0.30 per share price target, reflecting a >400% upside from this morning's opening price. Analyst Seth Lizee highlighted the successful interim results from SNT-5505 in myelofibrosis, with more data…

Join us again via Zoom tomorrow / Thursday 20 March for day 2 of the @NWRcomms Virtual Healthcare Conference with presentations still to come from Cyclopharm, CurveBeam AI, Neurotech International, Imricor, Hey Sister!, ECS Botanics, Vitrafy Life Sciences, Bio-Gene Technology &…

Kicking off at 9am AEDT tomorrow! @NWRcomms Virtual Healthcare Conference 2025 -- 19 & 20 March 19 ASX-listed & private life sciences companies presenting via Zoom, spanning therapeutics, medical devices, digital health & more. Additionally, Mark Pachacz of Bioshares will host…

NWR Virtual Healthcare Conference -- 19 & 20 March 2025 For the fourth year running we're showcasing a range of ASX-listed & private life sciences companies via Zoom, spanning therapeutics, medical devices, digital health & more. Mark Pachacz of Bioshares will again bring us an…

We're pleased to share that CEO Gary Phillips will present at the @NWRcomms Virtual Healthcare Conference on Wednesday, 19 March 2025, at 11:00am AEDT. Investors, shareholders, and interested parties are invited to register for the session here: ➡️tinyurl.com/32724vt6. A…

Maternity service closures in Darwin & Hobart has contributed to the worsening maternity crisis in Australia: lnkd.in/g2ufRxAK The situation presents an opportunity to revolutionise maternity care through innovative digital solutions, including HeraCARE. $HMD #medtech

$PYC has successfully closed the ~$91m institutional component of its Entitlement Offer, which will raise a total of ~$146m. This funds its pipeline of 4 first-in-class drug candidates with disease-modifying potential through major human data read-outs: buff.ly/3QJMgcJ

With major inflection points pending, @CurveBeamAI $CVB is in the market with its HiRise weight bearing CT scan technology, achieving record sales with the potential to redefine orthopedic imaging. KP Rx Founder & Managing Partner & CurveBeam Non-Executive Director Hashan De…

We’ve been mentioned on @ABCaustralia by Alan Kohler, following the announcement of our U.S. Department of Defense grants. We’re pleased to see Bio-Gene gaining recognition as we continue developing innovative, nature-derived insect control solutions. Watch the $BGT clip below…